Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)
Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing ...
Fintel on MSN3d
William Blair Initiates Coverage of Terns Pharmaceuticals (TERN) with Market Perform Recommendation
Fintel reports that on February 28, 2025, William Blair initiated coverage of Terns Pharmaceuticals (NasdaqGS:TERN) with a ...
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy ...
William Blair Initiates Coverage on Terns Pharmaceuticals (NASDAQ:TERN)
Equities researchers at William Blair started coverage on shares of Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) in a research note issued to investors on Friday, Marketbeat reports. The firm ...
Terns Pharmaceuticals initiated with a Market Perform at William Blair
William Blair initiated coverage of Terns Pharmaceuticals (TERN) with a Market Perform rating.Discover the Best Stocks and Maximize Your ...
Terns Pharmaceuticals provides program updates
Terns announced that management will participate in the TD Cowen 45th Annual Healthcare Conference taking place from March 3-5, 2025 in Boston ...
Terns Pharmaceuticals, Inc.: Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule ...
Morningstar6d
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 New TERN-701 data from ongoing U.S. healthy volunteer PK ...
Investing6d
Terns Pharmaceuticals reports progress in clinical trials
FOSTER CITY, Calif. - Terns Pharmaceuticals Inc. (NASDAQ: TERN), a clinical-stage biopharmaceutical company trading near its 52-week low of $3.72, announced updates on its ongoing development ...